FDA further signals its shift toward reducing harm from combustible tobacco use while still targeting smoking cessation with a pending notice on reducing nicotine in cigarettes.

"One of the first actions of [FDA's] comprehensive approach will be an advanced notice of proposed rulemaking (ANPRM) to seek input on the potential impacts of reducing nicotine levels in cigarettes to minimally or non-addictive levels," the agency states in the meeting notice.

Nicotine, meanwhile, gets a larger place as a solution in FDA's approach. "A key piece of the FDA’s comprehensive plan is a recognition that nicotine – while highly addictive – is delivered through products that represent a continuum of risk and is most harmful when delivered through combustible tobacco products. Accordingly, the Agency is committed to increasing access to and use of nicotine replacement therapy, which could help more smokers quit," the notice states.

FDA's Nicotine Replacement Standards Review Could Open Door For E-Cigarettes

More from Approval Standards

More from Pathways & Standards